ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...
Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.
Scientists discovered genes in the tuberculosis bacterium that becomes essential for the pathogen's survival when it's exposed to air through coughing. These genes could be targets for new therapies ...
Tuberculosis lives and thrives in the lungs. When the bacteria that cause the disease are coughed into the air, they are ...
During his address to Congress on March 4, Donald Trump alleged that the Biden administration had spent $8 million "for ...
Tuberculosis remains one of the most lethal infectious diseases caused by a single pathogen. According to the latest global ...
A new study reveals that a significant proportion of people living with HIV (PWH) on long-term antiretroviral therapy remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback